Rosen Law warns Park Ha investors

Rosen Law Firm has renewed its call for Park Ha Biological Technology Co., Ltd. investors to seek counsel ahead of a September 28, 2026 deadline in a securities class action tied to trading in the company’s shares. The notice, issued September 5, says the case covers purchasers of Park Ha securities between December 27, 2024 and July 8, 2025. (prnewswire.com) The lawsuit is pending in the U.S. District Court for the Southern District of New York under the caption *Thomas v. Park Ha Biological Technology Co., Ltd.*, case number 1:26-cv-06421. Public docket listings show the case was filed on July 28, 2026. (prnewswire.com) ### What exactly is Rosen telling investors to do? (courtlistener.com) Rosen Law Firm said investors who bought Park Ha securities during the class period may be entitled to compensation through a contingency-fee arrangement and can move to serve as lead plaintiff by September 28, 2026. Its latest reminder specifically highlighted investors with losses in excess of $100,000. The September 28 date is the lead-plaintiff deadline, not a trial date or settlement deadline. (prnewswire.com) In securities class actions, the lead plaintiff is the investor or group of investors seeking to represent the broader class. ### Which investors are covered by the case? (courtlistener.com) The proposed class includes people and entities that purchased or otherwise acquired Park Ha securities between December 27, 2024 and July 8, 2025, according to Rosen’s notice and the complaint summaries circulated by other plaintiffs’ firms. The complaint also ties the case to documents connected to the company’s December 27, 2024 initial public offering. (prnewswire.com) Park Ha began trading on Nasdaq under the ticker PHH on December 27, 2024 after pricing 1.2 million ordinary shares at $4.00 each, raising gross proceeds of about $4.8 million, company IPO materials show. Robbins LLP said the company later traded under ticker BYAH after using PHH until October 28, 2025. (accessnewswire.com) ### What does the complaint allege? Robbins LLP, summarizing the complaint, said the suit alleges Park Ha was the subject of a market-manipulation and fraudulent-promotion scheme involving social-media misinformation and people impersonating financial professionals. The complaint further alleges the company failed to disclose risks linked to that alleged activity. The same complaint summary says plaintiffs allege Park Ha’s public statements and risk disclosures omitted mention of false rumors and artificial trading activity, and that the IPO was structured with an unusually low public float that enabled manipulation. (prnewswire.com) Those are allegations in the lawsuit and have not been proven in court. ### What kind of company is Park Ha? Park Ha Biological Technology said in its IPO materials that it focuses on private skincare labels, direct skincare product sales and franchise alliance promotions in China. (sec.gov) Robbins LLP separately described the business as developing and selling skincare and cosmetics products under the “Park Ha” brand through an online-to-offline model. The company’s IPO announcement said it planned to use proceeds to expand direct stores in China, acquire product patents and secure ingredient suppliers. (robbinsllp.com) ### What happens next in the case? The Southern District of New York docket shows the case is before Judge Denise L. Cote. Investors seeking appointment as lead plaintiff must move the court by September 28, 2026, according to Rosen and other firms tracking the case. (robbinsllp.com) That deadline is the next concrete milestone. After it passes, the court can decide who will serve as lead plaintiff and which lawyers will lead the proposed class action on behalf of Park Ha investors. (courtlistener.com) (pacermonitor.com) (nasdaq.com) (sec.gov)